Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Therapeutic antibodies largely populate the list of top biologic drugs since years. They revolutionize the treatment of pathologies falling into major disease areas, including cancer, chronic inflammatory diseases, allergy and infectious diseases. More and more antibodies are being proposed to treat an expanding number of pathologies, but in parallel more and more resistance/escape mechanisms are described, forcing academia and industry to search for alternative concepts to prevent unresponsiveness or treat resistant patients. Not only methodological and technological advances, but also paradigm-shifting concepts are developed to face these challenges. This Keystone Symposia conference aims to present the state-of-the-art in antibody therapeutics, repertoires & deep learning, bispecific antibodies and engineering from industry and academia. Specifically, we wish to highlight and discuss recent breakthroughs in identifying therapeutics from volunteers/patients, understanding vaccination and mode of delivery, modalities for half-life extensions and involvement of complement in the antibodies mode of action. We think this upcoming period will showcase the rise of bispecifics in the therapeutic landscape and propose to highlight the technologies to develop them, their functionalities, and clinical efficacies, particularly in immune-oncology.